IMMUNIC, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IMMUNIC, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($97.17M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($100.51M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($93.61M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($120.41M) | Feb 22, 2024 |
| FY2021 | Dec 31, 2021 | ($21.19M) | Feb 24, 2022 |
| FY2021 | Sep 30, 2021 | ($19.29M) | Feb 24, 2022 |
| FY2021 | Jun 30, 2021 | ($17.93M) | Feb 24, 2022 |
| FY2021 | Mar 31, 2021 | ($34.53M) | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | ($11.16M) | Feb 24, 2022 |
| FY2021 | Sep 30, 2020 | ($12.91M) | Feb 24, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($103.23M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($98.05M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($99.22M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($119.49M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($91.67M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($48.97M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($37.03M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($12.00M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($52.66M) | Mar 4, 2019 |
| FY2018 | Dec 31, 2016 | ($41.27M) | Mar 4, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.98M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $80.05M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $83.22M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $71.26M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $61.12M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $38.64M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $22.51M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $9.60M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $39.34M | Mar 4, 2019 |
| FY2018 | Dec 31, 2016 | $30.05M | Mar 4, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($85.81M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($84.77M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($70.83M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($65.14M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($83.23M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($46.12M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($28.55M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($9.74M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($40.40M) | Mar 4, 2019 |
| FY2018 | Dec 31, 2016 | ($35.77M) | Mar 4, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $161.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $264.0K | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $334.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $112.0K | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $67.0K | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $146.0K | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $55.0K | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $32.0K | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $685.0K | Mar 4, 2019 |
| FY2018 | Dec 31, 2016 | $556.0K | Mar 4, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.05M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $40.87M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $54.30M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $127.75M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $139.10M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $167.86M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $65.96M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $13.37M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $60.38M | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | $64.03M | Mar 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.73M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $22.44M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $25.37M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $14.07M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $11.99M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $9.08M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $7.59M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.92M | Mar 16, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.67M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $18.43M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $28.93M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $113.68M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $127.12M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $158.79M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $58.36M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($25.74M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($13.34M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $58.45M | Mar 4, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | $32.97M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $32.97M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $32.97M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Mar 16, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($608.57M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($511.40M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($410.89M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($317.28M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($196.87M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($103.93M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($59.91M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($24.98M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($295.95M) | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | ($243.83M) | Mar 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.48M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $35.67M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $46.67M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $106.75M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $86.86M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $127.45M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $29.37M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $13.07M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $56.90M | Mar 4, 2019 |
| FY2018 | Dec 31, 2016 | $59.99M | Mar 4, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Feb 22, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Feb 24, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Feb 24, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Feb 24, 2022 |
| FY2021 | Mar 31, 2021 | (1) | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Feb 24, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Feb 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Feb 22, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Feb 24, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Feb 24, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Feb 24, 2022 |
| FY2021 | Mar 31, 2021 | (1) | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Feb 24, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Feb 24, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 90.15M | Feb 26, 2026 |
| FY2024 | Dec 31, 2024 | 90.15M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 45.18M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 39.31M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 26.34M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 21.17M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 10.74M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 846,953 | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 42.37M | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | 32.14M | Mar 13, 2018 |